R. Greil

发表

Hematopoietic growth factors: ESMO recommendations for the application.

R. Greil, O. Psenak, R. Greil, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

R. Greil, K. Harrington, A. Psyrri, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.

J. Machiels, R. Swaby, R. Mesía, 2024, The Lancet. Oncology.